Development of Therapeutics for Biodefense and Emerging Infectious Diseases
$2,284,288N01FY2022AINIH
Venatorx Pharmaceuticals, Inc., Malvern PA
Investigators
Abstract
To support the development of therapeutic products effective against resistant bacterial infections.
View original record on NIH RePORTER →